Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · mixedMedium impact
Esc

Summit Therapeutics Stock Rises 6% After AstraZeneca Investment

SEC / Summit Therapeutics2 min read6 sources

Why did Summit Therapeutics stock rise 6%?

Summit Therapeutics (SMMT) stock rose about 6% to near $16.49 on Tuesday after AstraZeneca agreed to invest $2 billion for a 12% stake, a vote of confidence in its cancer drug ivonescimab.

Key numbers

AstraZeneca investment$2B~12% stake (10.6% fully diluted)
Premarket move (Sep 29)+17%faded to about +6% by mid-morning; other reports cite up to 22%
Deal price per share$18.36+18.6% vs Sep 28 close of $15.48
Price at 11:29 ET$16.49+6.5% vs $15.48 prior close
Estimated cash after deal$2.5Bvs about $690M in July
FDA decision deadlineNov 14, 2026EGFR-mutated lung cancer

What happened

Summit Therapeutics (SMMT) stock rose about 6% to near $16.49 on Tuesday after AstraZeneca agreed to invest $2 billion for a 12% stake, a vote of confidence in its cancer drug ivonescimab. Shares had jumped 17% before the market opened, but most of that gain faded during the day. AstraZeneca pays $18.36 a share, 18.6% above Monday's closing price. The two companies will also test ivonescimab alongside AstraZeneca's antibody-drug conjugates (drugs that carry chemotherapy straight to tumor cells).

Why it matters

Summit Therapeutics was running short of cash, with about $690 million in July, less than a year of funding. The $2 billion investment lifts its estimated cash to about $2.5 billion and shows a large drugmaker backing its cancer drug before a U.S. FDA decision due by November 14. It also adds to a race among big drug companies, including Merck, Pfizer and Bristol Myers Squibb, to develop this type of drug.

Who this affects

Marketmixed
Medium impact
Biotech investors cheered the backing, though most gains faded.
Companybullish
High impact
Summit gets funding and a partner; shareholders face dilution.
Competitorsmixed
Medium impact
Licensor Akeso rose 10%; rival developers face tougher competition.
Industrybullish
Medium impact
Big drugmakers keep buying into PD-1/VEGF cancer drugs.

Summit Therapeutics vs Akeso, AstraZeneca

Summit TherapeuticsSMMT$16.49+6.5%
Akeso9926.HKHK$102.5+10%
AstraZenecaAZN—+1.2% (London)

As of 2026-09-29

How we got here

  1. AstraZeneca and Summit announce $2B investment and clinical collaboration after the market closes.

  2. Summit jumps 17% premarket, then gives back most of the gain by mid-morning.

  3. Akeso, which developed ivonescimab, rises 10% in Hong Kong trading.

What to watch

  • FDA decision on ivonescimab for EGFR-mutated lung cancer, due on or before this date.2026-11-14
  • Deal expected to close within about a week of the announcement.2026-10
  • ESMO cancer conference: ivonescimab biliary tract data and sone-ve phase 3 gastric cancer results.2026-10

Educational content only. Not investment advice.

More briefsAll briefs →